NCT00607113View on ClinicalTrials.gov

Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Neuroendocrine Carcinoma
Interventions
DRUG

Avastin

15 mg/kg By Vein Over 90 Minutes Every 21 Days

DRUG

RAD001

10 mg By Mouth Daily For 21 Days

Trial Locations (1)

77030

U.T.M.D. Anderson Cancer Center, Houston

Sponsors

Collaborators (2)

Novartis
Genentech, Inc.
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00607113 - Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma | Biotech Hunter | Biotech Hunter